Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMIXC7G)

Drug Name
Zoledronate Drug Info
Synonyms
Aclasta; Reclast; ZOL; Zometa; Novartis brand of zoledronic acid; Zoledronic acid; Zometa Concentrate; Bisphosphonate 3; CGP 42446; CGP 42446A; Aclasta (TN); CGP 42'446; CGP-42446; KS-1132; Reclast (TN); Zoledronic acid (INN); Zoledronic acid [USAN:INN]; Zomera (TN); Zometa (Novartis); Zometa (TN); CGP-42'446; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
Therapeutic ClassBone Density Conservation Agents
Cross-matching ID
PubChem CID
68740
ChEBI ID
CHEMBL924
CAS Number
CAS 118072-93-8
TTD Drug ID
D0VM2L
VARIDT Drug ID
DR01473

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Endocrine and other factor-regulated calcium reabsorpti... 1.96 1.25e-2 49/53 (92.45%) PLCB1;FXYD2;ATP1A1;...
Complement and coagulation cascades 1.93 1.25e-2 76/85 (89.41%) CLU;CR2;SERPINA5;...
Thyroid hormone signaling pathway 1.90 8.36e-3 112/121 (92.56%) ACTB;PLCB1;NCOA3;...
Salivary secretion 1.80 3.76e-2 76/93 (81.72%) PLCB1;CST1;CST3;...
Rheumatoid arthritis -1.76 3.25e-2 78/93 (83.87%) ATP6V1G1;HLA-DPA1;HLA-DPB1;...
Ribosome -1.83 1.88e-2 113/158 (71.52%) RPL19;MRPS16;RPS8;...
Type I diabetes mellitus -1.86 1.26e-2 38/43 (88.37%) HLA-DPA1;HLA-C;HLA-DPB1;...
Antigen processing and presentation -1.91 9.64e-3 60/78 (76.92%) HLA-DPA1;HLA-C;HLA-DPB1;...
Graft-versus-host disease -1.96 1.08e-2 32/42 (76.19%) HLA-DPA1;HLA-C;HLA-DPB1;...
Viral protein interaction with cytokine and cytokine re... -2.02 7.23e-3 84/100 (84%) TNF;CCL23;CXCL11;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12.5uM 72H
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H